Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A Systematic Review and Meta-analysis

Overview

Journal Sultan Qaboos Univ Med J

Specialty General Medicine

Date 2024 Sep 5

PMID 39234312

Authors

M Kanimozhi

Manisha Bisht

Sikha Morang

Surabhi Thapliyal

Manbir S Bassan

Shailendra Handu

Affiliations

Soon will be listed here.

Abstract

This meta-analysis investigated efficacy of dapagliflozin as adjunctive therapy for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stages 2-5. A systematic search was conducted of selected databases for randomised controlled trials that reported the mean change in estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) from baseline. Out of 1,682 identified studies, 9 trials comprising 13,057 patients were included. A pooled estimate of 5 studies indicated that dapagliflozin did not affect eGFR; however, in 2 studies, it significantly reduced chronic eGFR decline compared to placebo (mean difference [MD] ± 2.74; 95% confidence interval [CI]: 1.55, 3.92; <0.00001). Additionally, a pooled estimate of 4 studies showed that dapagliflozin significantly reduced UACR (MD -23.99%; 95% CI: -34.82--13.15; <0.0001; I = 0%). Therefore, long-term use of dapagliflozin significantly attenuates eGFR decline and reduces albuminuria in patients with T2DM and CKD.

References

Anders H, Huber T, Isermann B, Schiffer M . CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018; 14(6):361-377. DOI: 10.1038/s41581-018-0001-y. View

Levey A, Grams M, Inker L . Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease. N Engl J Med. 2022; 386(22):2120-2128. DOI: 10.1056/NEJMra2201153. View

Mosenzon O, Wiviott S, Cahn A, Rozenberg A, Yanuv I, Goodrich E . Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019; 7(8):606-617. DOI: 10.1016/S2213-8587(19)30180-9. View

Pollock C, Stefansson B, Reyner D, Rossing P, Sjostrom C, Wheeler D . Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised,.... Lancet Diabetes Endocrinol. 2019; 7(6):429-441. DOI: 10.1016/S2213-8587(19)30086-5. View

Jongs N, Greene T, Chertow G, McMurray J, Langkilde A, Correa-Rotter R . Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021; 9(11):755-766. DOI: 10.1016/S2213-8587(21)00243-6. View

Mosenzon O, Raz I, Wiviott S, Schechter M, Goodrich E, Yanuv I . Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes Care. 2022; 45(10):2350-2359. PMC: 9862307. DOI: 10.2337/dc22-0382. View

Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, Flottorp S . Grading quality of evidence and strength of recommendations. BMJ. 2004; 328(7454):1490. PMC: 428525. DOI: 10.1136/bmj.328.7454.1490. View

Toyama T, Neuen B, Jun M, Ohkuma T, Neal B, Jardine M . Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019; 21(5):1237-1250. DOI: 10.1111/dom.13648. View

Kashiwagi A, Maegawa H . Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017; 8(4):416-427. PMC: 5497037. DOI: 10.1111/jdi.12644. View

10.

Heerspink H, Greene T, Tighiouart H, Gansevoort R, Coresh J, Simon A . Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019; 7(2):128-139. DOI: 10.1016/S2213-8587(18)30314-0. View

11.

Jafar T . FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?. Lancet. 2021; 398(10297):283-284. DOI: 10.1016/S0140-6736(21)01242-3. View

12.

Neuen B, Young T, Heerspink H, Neal B, Perkovic V, Billot L . SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019; 7(11):845-854. DOI: 10.1016/S2213-8587(19)30256-6. View

13.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

14.

Heerspink H, Langkilde A, Wheeler D . Dapagliflozin in Patients with Chronic Kidney Disease. Reply. N Engl J Med. 2021; 384(4):389-390. DOI: 10.1056/NEJMc2032809. View

15.

Berman N, Parker R . Meta-analysis: neither quick nor easy. BMC Med Res Methodol. 2002; 2:10. PMC: 122061. DOI: 10.1186/1471-2288-2-10. View

16.

Fioretto P, Del Prato S, Buse J, Goldenberg R, Giorgino F, Reyner D . Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab. 2018; 20(11):2532-2540. PMC: 6175614. DOI: 10.1111/dom.13413. View

17.

Heerspink H, Sjostrom C, Inzucchi S, Hallow M, Cain V, Rossing P . Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. Diabetes Obes Metab. 2018; 21(3):720-725. PMC: 6590413. DOI: 10.1111/dom.13579. View

18.

Mosenzon O, Wiviott S, Heerspink H, Dwyer J, Cahn A, Goodrich E . The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021; 44(8):1805-1815. PMC: 8385472. DOI: 10.2337/dc21-0076. View

19.

Heerspink H, Jongs N, Chertow G, Langkilde A, McMurray J, Correa-Rotter R . Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021; 9(11):743-754. DOI: 10.1016/S2213-8587(21)00242-4. View

20.

Huang Y, Lu W, Lu H . The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy. Diabetol Metab Syndr. 2022; 14(1):47. PMC: 8966174. DOI: 10.1186/s13098-022-00815-y. View